Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease

被引：1

作者：

Donohue, James ^{[1
]}

Kerwin, Edward ^{[2
]}

Sethi, Sanjay ^{[3
]}

Haumann, Brett ^{[4
]}

Pendyala, Srikanth ^{[4
]}

Dean, Lorna ^{[4
]}

Barnes, Chris N. ^{[4
]}

Moran, Edmund J. ^{[4
]}

Crater, Glenn ^{[4
]}

机构：

[1] UNC Sch Med, Pulm Med, Chapel Hill, NC USA

[2] Clin Res Inst Southern Oregon, PC, Medford, OR USA

[3] SUNY Buffalo, Buffalo, NY USA

[4] Theravance Biopharma US Inc, San Francisco, CA 94080 USA

来源：

DATA IN BRIEF | 2019年 / 26卷

关键词：

Chronic obstructive pulmonary disease; COPD; Long-acting muscarinic antagonist; Nebulization; Revefenacin;

D O I：

10.1016/j.dib.2019.104277

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

This article contains information on the experimental design and methods on how the safety and tolerability data concerning patients with moderate to very severe chronic obstructive pulmonary disease (COPD) were obtained. This is in addition to our original research article. [1] We have also provided information on the clinical laboratory tests that were conducted. Further interpretation and discussion of the data are demonstrated in the article "Revefenacin, a Once-daily, Lung-selective, Long-acting Muscarinic Antagonist for Nebulized Therapy: Safety and Tolerability Results of a 52-week Phase 3 Trial in Moderate to Very Severe Chronic Obstructive Pulmonary Disease." [1] (c) 2019 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

引用

页数：7

共 2 条

[1] Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials [J].